For those that missed it in the H1, probably the most pertinent part:
'...Strong news flow will continue in 2017 as we report on the clinical progress of CAVATAK as a potential new treatment in the fast-growing field of cancer immunotherapy.'
Bring it on...
Good buying opportunity atm, in my opinion...
ML
For those that missed it in the H1, probably the most pertinent...
Add to My Watchlist
What is My Watchlist?